ResearcherGachon University Medical CenterActive in the last 2 years
Eui Joo Kim
Matched on ORCID iD 0000-0001-5573-7083; OpenAlex author ID A5075059518. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 30
2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 6
- Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Co-author DOI 10.1093/clinchem/hvaf066↗
- Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin leve… Co-author DOI 10.1038/s41416-023-02474-w↗
- Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum … Co-author DOI 10.1038/s41416-023-02520-7↗
- NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression. Co-author DOI 10.3390/ijms21134646↗
- Ursodeoxycholic acid suppresses epithelial-mesenchymal transition and cancer stem cell formation by reducing the levels of peroxiredoxin II and reactive oxygen… Co-author DOI 10.3892/or.2017.6045↗
- Successful hemostasis using a covered self-expandable metallic stent for spurting hemobilia in patients with advanced pancreatic cancer-induced portal biliopat… Co-author DOI 10.1016/j.gie.2016.05.042↗
Closest collaborators
The 25 strongest of 30 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Woo Jin Lee · 3 shared papers, 2024–2025 · strength 0.55
- Paper Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic … DOI 10.1093/clinchem/hvaf066↗
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Chang‐Hwan Park · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Jae Woo Kim · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Mi‐Suk Park · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Y. Choi · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Si Young Song · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Jung Hyun Jo · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Hyungsik Roger Moon · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Dong Uk Kim · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Seung Ok Lee · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Ho Gak Kim · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Yong‐Tae Kim · 2 shared papers, 2024 · strength 0.33
- Paper Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adeno… DOI 10.1038/s41416-023-02474-w↗
- Paper Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic … DOI 10.1038/s41416-023-02520-7↗
- Jae Hee Cho · 3 shared papers, 2016–2020 · strength 0.30
- Paper NRF2 Knockdown Resensitizes 5-Fluorouracil-Resistant Pancreatic Cancer Cells by Suppressing HO-1 and ABCG2 Expression. DOI 10.3390/ijms21134646↗
- Paper Ursodeoxycholic acid suppresses epithelial-mesenchymal transition and cancer stem cell formation by reducing the levels… DOI 10.3892/or.2017.6045↗
- Paper Successful hemostasis using a covered self-expandable metallic stent for spurting hemobilia in patients with advanced p… DOI 10.1016/j.gie.2016.05.042↗
- Sung‐Sik Han · 1 shared paper, 2025 · strength 0.22
- Min Kyu Jung · 1 shared paper, 2025 · strength 0.22
- Min Kyeong Kim · 1 shared paper, 2025 · strength 0.22
- Jin‐Hyeok Hwang · 1 shared paper, 2025 · strength 0.22
- Dong‐Won Ahn · 1 shared paper, 2025 · strength 0.22
- Jung Won Chun · 1 shared paper, 2025 · strength 0.22
- Sang Hyub Lee · 1 shared paper, 2025 · strength 0.22
- Sang‐Jae Park · 1 shared paper, 2025 · strength 0.22
- Sun‐Young Kong · 1 shared paper, 2025 · strength 0.22
- Yun‐Hee Kim · 1 shared paper, 2025 · strength 0.22
- Sang Myung Woo · 1 shared paper, 2025 · strength 0.22
- Kwang Hyuck Lee · 1 shared paper, 2024 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.